Brachytherapy, Desmoid Tumor, Radioactive Iodine-125 Seed Implantation
Conditions
Brief summary
This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 (I-125) seed implantation (RISI) for recurrent desmoid tumor. A multicenter retrospective study reviewed 38 recurrent desmoid tumor patients receiving RISI from July 2013 to July 2021.The clinical outcomes including overall response rate (ORR), disease control rate (DCR), local control time (LCT), overall survival (OS), adverse events (AEs), and symptom relief rate were statistically assessed.
Detailed description
Desmoid tumor was characterized by a high potential of recurrence even following initial definitive treatment. There were considerable controversies regarding the management of recurrent desmoid tumor. This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 (I-125) seed implantation (RISI) for recurrent desmoid tumor. 38 patients, diagnosed with recurrent desmoid tumor, undergoing RISI in 3 different centers including Peking University Third Hospital, First Affiliated Hospital of the Army Medical University, and Shengli Oilfield Central Hospital from July 2013 to July 2021 were reviewed consecutively. The clinical outcomes including overall response rate (ORR), disease control rate (DCR), local control time (LCT), overall survival (OS), adverse events (AEs), and symptom relief rate were statistically assessed.
Interventions
RADIATIONCT-guided radioactive iodine-125 seed implantation
The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.
Sponsors
First Affiliated Hospital of the Army Medical University
Shengli Oilfield Hospital
Peking University Third Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
13 Years to 75 Years
Inclusion criteria
1\) recurrent desmoid tumor confirmed by pathologic or imaging diagnosis; 2) disease size ≥1 cm and ≤ 10 cm; 3) medically inoperable or individual refusal to resection; 4) Karnofsky performance status (KPS) ≥ 60; 5) adequate hematological reserves, hepatic function, renal function and heart function; 7) expected survival \> 3 months.
Exclusion criteria
1\) unconfirmed mass; 2) tumor invading the skin or mucous membrane; 2) patients with severe bleeding tendency; 3) patients with active infectious disease, trauma and severe wounds; 4) patients with any mental disorder; 5) patients with other somatic comorbidities of clinical concern; 6) pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local control time (LCT) | 8 years | LCT was defined as the time from seed implantation to local progression |
| objective response rate (ORR) | 6 months | ORR was calculated from patients achieving CR and PR |
| disease control rate (DCR) | 6 months | DCR was likewise calculated from the patients of CR, PR and SD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival (OS) | 8 years | OS was defined as the time from RISI to death from any cause |
| adverse events (AEs) | 8 years | The AEs were evaluated as per Radiation Therapy Oncology Group (RTOG) guidelines. |
| symptom relief rate | 8 years | symptom relief rate was calculated from the patients achieving relief after treatment. |
Countries
China
Outcome results
None listed